“Cingulate has achieved major development milestones in the second quarter of 2024 relating to our first product candidate, CTx-1301 for the treatment of ADHD. The combination of the Food and Drug Administration clearance for filing for marketing approval and completion of the registration batches keeps us on the path to a targeted NDA submission in the first half of 2025. We are further encouraged by a recent M&A transaction announced in the ADHD space as we continue to explore licensing opportunities for CTx-1301 in and outside the United States,” said Shane Schaffer, Chief Executive Officer of Cingulate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
- Cingulate Inc trading halted, news pending
- Cingulate files to sell 6.63M shares of common stock for holders
- Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
- Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event